Clinical Trial

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10). We hypothesize that ticagrelor is associated with better pharmacodynamic effects (i.e., lower platelet reactivity and high platelet reactivity rates) compared with clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention with a high ABCD-GENE score.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-01-19; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2024-04-22
Trial Details
NCT Number NCT06228456
Lead Sponsor University of Florida
Collaborators: Scott R. MacKenzie Foundation
Conditions Coronary Artery Disease
Enrollment 50 participants
Start Date 2024-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-05